ABT-767
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fallopian Tube
Conditions
Fallopian Tube, Primary Peritoneal Cancer, Solid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and Ovarian
Trial Timeline
May 6, 2011 → Nov 30, 2017
NCT ID
NCT01339650About ABT-767
ABT-767 is a phase 1 stage product being developed by AbbVie for Fallopian Tube. The current trial status is completed. This product is registered under clinical trial identifier NCT01339650. Target conditions include Fallopian Tube, Primary Peritoneal Cancer, Solid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and Ovarian.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01339650 | Phase 1 | Completed |
Competing Products
20 competing products in Fallopian Tube